Ten take home lessons from the first 10 years of the CTN and 10 recommendations for the future

American Journal of Drug and Alcohol Abuse

Volumn 37, Issue 5, 2011, Pages 275-282

  Carroll, Kathleen M ^a   Ball, Samuel A ^a   Jackson, Ron ^b   Martino, Steve ^a   Petry, Nancy M ^c   Stitzer, Maxine L ^d   Wells, Elizabeth A ^b   Weiss, Roger D ^e,f  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MCLEAN HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Behavioral trials; Clinical Trials Network; Methodology

Indexed keywords

ADDICTION; ARTICLE; BEHAVIOR THERAPY; BEHAVIORAL RESEARCH; BEHAVIORAL TRIAL; CLINICAL TRIAL (TOPIC); CLINICAL TRIAL NETWORK; COMMUNITY PROGRAM; COMORBIDITY; COMPARATIVE STUDY; DRUG DEPENDENCE TREATMENT; EMPIRICALLY VALIDATED THERAPY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE ACCESS; INFORMATION DISSEMINATION; INVOLUNTARY COMMITMENT; METHODOLOGY; OUTCOME ASSESSMENT; PUBLIC HEALTH; QUALITY CONTROL; REIMBURSEMENT; SAFETY; SECONDARY ANALYSIS; THERAPY EFFECT; VALIDATION THERAPY;

CLINICAL TRIALS AS TOPIC; COMMUNITY HEALTH SERVICES; HUMANS; NATIONAL INSTITUTE ON DRUG ABUSE (U.S.); OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 80052254303     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2011.596978     Document Type: Article

References (75)

1. Institute of Medicine. Bridging the Gap between Practice and Research: Forging Partnerships with Community-Based Drug and Alcohol Treatment. Washington, DC: National Academy Press, 1998
2. Tai B, Straus MM, Liu D, Sparenborg S, Jackson R, McCarty D. The first decade of the National Drug Abuse Treatment Clinical Trials Network: Bridging the gap between research and practice to improve drug abuse treatment. J Subst Abuse Treat 2010; 38(Suppl. 1):S4-S13.
3. Hanson GR, Leshner AI, Tai B. Putting drug abuse research to work in real-life settings. J Subst Abuse Treat 2002; 23:69-70. (Pubitemid 36151687)
4. Nunes EV, Ball SA, Booth R, Brigham G, Calsyn DA, Carroll KM, Feaster DJ, Hien D, Hubbard RL, Ling W, Petry NM, Rotrosen J, Selzer J, Stitzer M, Tross S, Wakim P, Winhusen T, Woody G. Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: Have we chosen the best designs? J Subst Abuse Treat 2010; 38(Suppl. 1):S97-S112, PMCID: PMC2909698.
5. Chambless DL, Hollon SD. Defining empirically supported therapies. J Consult Clin Psychol 1998; 66(1):7-18. (Pubitemid 28086807)
6. Chambless DL, Ollendick TH. Empirically supported psychological interventions: Controversies and evidence. Annu Rev Psychol 2001; 52:685-716. (Pubitemid 33705589)
7. Onken LS, Blaine JD, Battjes R. Behavioral therapy research: A conceptualization of a process. In Innovative Approaches for Difficult to Treat Populations. Hennegler SW, Amentos, R, eds. Washington, DC: American Psychiatric Press, 1997; 477-485.
8. Rounsaville BJ, Carroll KM, Onken LS. A stage model of behavioral therapies research: Getting started and moving on from Stage I. Clin Psychol: Sci Pract 2001; 8:133-142. (Pubitemid 33739032)
9. Fixsen DL, Naoom SF, Blase KA, Friedman RM, Wallace F, Implementation Research: A Synthesis of the Literature, University of South Florida, Louis de la Parte Florida Mental Health Institute, the National Implementation Research Network (FMHI Publication #231), Tampa: FL, 2005.
10. Carroll KM, Rounsaville BJ. Bridging the gap between research and practice in substance abuse treatment: A hybrid model linking efficacy and effectiveness research. Psychiatr Serv 2003; 54:333-339. (Pubitemid 36753005)
11. Baer JS, Ball SA, Campbell BK, Miele GM, Schoener EP, Tracy K. Training and fidelity monitoring of behavioral interventions in multi-site addictions research. Drug Alcohol Depend 2007; 87:107-118. (Pubitemid 46215936)
12. Carroll KM, Rounsaville BJ. A vision of the next generation of behavioral therapies research in the addictions. Addiction 2007; 102(6):850-862, discussion 863-869. PMCID: PMC2148498. (Pubitemid 46802229)
13. Hien DA, Jiang H, Campbell AN, Hu MC, Miele GM, Cohen LR, Brigham GS, Capstick C, Kulaga A, Robinson J, Suarez- Morales L, Nunes EV. Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDAs Clinical Trials Network. Am J Psychiatry 2010; 167(1):95-101.
14. Roll JM, Petry NM, Stitzer ML, Brecht ML, Peirce JM, McCann MJ, Blaine J, MacDonald M, Dimaria J, Lucero L, Kellogg S. Contingency management for the treatment of methamphetamine use disorders. Am J Psychiatry 2006; 163(11):1993-1999. (Pubitemid 44807792)
15. Burlew AK, Feaster D, Brecht ML, Hubbard R. Measurement and data analysis in research addressing health disparities in substance abuse. J Subst Abuse Treat 2009; 36(1):25-43.
16. Wells EA, Saxon AJ, Calsyn DA, Jackson TR, Donovan DM. Study results from the Clinical Trials Networks first 10 years: Where do they lead? J Subst Abuse Treat 2010; 38 (Suppl. 1):S14-S30.
17. Mohr DC, Spring B, Freedland KE, Beckner V, Arean P, Hollon SD, Ockene J, Kaplan R. The selection and design of control conditions for randomized controlled trials of psychological interventions. Psychother Psychosom 2009; 78(5):275-284.
18. Kazdin AE. Comparative outcome studies of psychotherapy: Methodological issues and strategies. J Consult Clin Psychol 1986; 54:95-105. (Pubitemid 17022266)
19. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008; 165(2):179-187. (Pubitemid 351704516)
20. Prendergast M, Podus D, Finney JW, Greenwell L, Roll JM. Contingency management for treatment of substance use disorders: A meta-analysis. Addiction 2006; 101: 1546-1560. (Pubitemid 44527186)
21. Peirce JM, Petry NM, Stitzer ML, Blaine JD, Kellog S, Satterfield F, Schwartz M, Krasnansky J, Pencer E, Silva-Vazquez L, Kirby KC, Royer-Malvestuto C, Roll JM, Cohen A, Copersino ML, Kolodner K, Li R, and for the Clinical Trials Network. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical Trials Network Study. Arch Gen Psychiatry 2006; 63:201-208. (Pubitemid 43213882)
22. Petry NM, Peirce JM, Stitzer ML, Blaine JD, Roll JM, Cohen A, Obert J, Killeen T, Saladin ME, Cowell M, Kirby KC, Sterling R, Royer-Malvestuto C, Hamilton J, Booth RE, Macdonald M, LiebertM, Rader L, Burns R, DiMaria J, Copersino ML, Stabile PO, Kolodner K, Li R, and for the Clinical Trials Network. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: A National Drug Abuse Clinical Trials Network Study. Arch Gen Psychiatry 2006; 62:1148-1156.
23. Olmstead TA, Sindelar JL, Petry NM. Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs. Drug Alcohol Depend 2007; 87:175-182. (Pubitemid 46215922)
24. Olmstead TA, Sindelar JL, Petry NM. Clinic variation in the cost-effectiveness of contingency management. Am J Addict 2007; 16(6):457-460. (Pubitemid 350223228)
25. Sindelar JL, Olmstead TA, Peirce J. Cost-effectiveness of prize-based contingency management in methadone maintenance programs. Addiction 2007; 102:1463-1471. (Pubitemid 47246989)
26. Kirby KC, Benishek LA, Dugosh KL, Kerwin ME. Substance abuse treatment providers beliefs and objections regarding contingency management: Implications for dissemination. Drug Alcohol Depend 2006; 85(1):19-27. (Pubitemid 44376548)
27. Simpson DD, Joe GW, Brown BS. Treatment retention and follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav 1997; 11:294-307. (Pubitemid 28046591)
28. Amaro H, Arevalo S, Gonzalez G, Szapocznik J, Iguchi MY. Needs and scientific opportunities for research on substance abuse treatments among Hispanic adults. Drug Alcohol Depend 2006; 84S:S64-S75. (Pubitemid 44150622)
29. Carroll KM, Martino S, Suarez-Morales L, Ball SA, Miller WR, Rosa C, Anez LM, Paris MP, Nich C, Frankforter TL, Matthews J, Szapocznik J. A multisite randomized effectiveness study of motivational enhancement therapy for Spanishspeaking substance abusers. J Consult Clin Psychol 2009; 77:993-999, PMCID: PMC 2792592.
30. Ducharme LJ, Knudsen HK, Roman PM, Johnson JA. Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. J Subst Abuse Treat 2007; 32(4):321-329. (Pubitemid 46661128)
31. McCarty D, Fuller B, Kaskutas LA, Wendt WW, Nunes EV, Miller M, Forman R, Magruder KM, Arfken C, Copersino M, Floyd A, Sindelar J, Edmundson E. Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug Alcohol Depend 2008; 92(1-3):200-207. (Pubitemid 350218202)
32. Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid MC, Muir J, Buchan B, Orr D, Woody GE, Krejci J, Ziedonis D, for the Buprenorphine/Naloxone Collaborative Study Group. A multicenter randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005; 100:1090-1100. (Pubitemid 41113602)
33. Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, Patkar A, Publicker M, McCain K, Potter JS, Forman R, Vetter V, McNicholas L, Blaine J, Lynch KG, Fudala P. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. J Am Med Assoc 2008; 300(17):2003-2011.
34. Ball SA, Martino S, Nich C, Frankforter TL, Van Horn D, Crits-Christoph P, Woody GE, Obert JL, Farentinos C, Carroll KM. Site matters: Multisite randomized trial of motivational enhancement therapy in community drug abuse clinics. J Consult Clin Psychol 2007; 75(4):556-567, PMCID: PMC2148493. (Pubitemid 47454576)
35. Carroll KM, Ball SA, Nich C, Martino S, Frankforter T, Crits-Christoph P, Farentinos C, Mikulich-Gilbertson S, Morgenstern J, Obert JL, Polcin D, Snead N, Woody GE, and for the Clinical Trials Network. Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: A multisite effectiveness study. Drug Alcohol Depend 2006; 81:301-312, PMCID: PMC2386852. (Pubitemid 43152457)
36. Petry NM, Roll JM, Rounsaville BJ, Ball SA, Stitzer M, Peirce JM, Blaine J, Kirby KC, McCarty D, Carroll KM. Serious adverse events in randomized psychosocial treatment studies: Safety or arbitrary edicts? J Consult Clin Psychol 2008; 76(6):1076-1082, PMCID: PMC2756150.
37. Petry NM, Kolodner KB, Li R, Peirce JM, Roll JM, Stitzer ML, Hamilton JA. Prize-based contingency management does not increase gambling. Drug Alcohol Depend 2006; 83(3):269-273.
38. Barlow DH. Negative effects from psychological treatments: A perspective. Am Psychologist 2010; 65(1):13-20.
39. Santa Ana E, Martino S, Ball SA, Nich C, Carroll KM. What is usual about "treatment as usual": Audiotaped ratings of standard treatment in the Clinical Trials Network. J Subst Abuse Treat 2008; 35:369-379, PMCID: PMC2712113.
40. Bamatter W, Carroll KM, Anez LM, Paris Jr M, Ball SA, Nich C, Frankforter TL, Suarez-Morales L, Szapocznik J, Martino S. Informal discussions in substance abuse treatment sessions with Spanish-speaking clients. J Subst Abuse Treat 2010; 39(4):353-363.
41. Martino S, Ball SA, Nich C, Frankforter TL, Carroll KM. Informal discussions in substance abuse treatment sessions. J Subst Abuse Treat 2009; 36(4):366-375, PMCID: PMC2705985.
42. Martino S, Ball S, Nich C, Frankforter TL, Carroll KM. Correspondence of motivational enhancement treatment integrity ratings among therapists, supervisors, and observers. Psychother Res 2009; 19(2):181-193, PMCID: PMC2782382.
43. Martino S, Brigham G, Higgins C, Gallon S, Freese TE, Albright LM, Hulsey EG, Storti SA, Perl H, Nugent CD, Pintello D, Condon TP. Partnerships and pathways of dissemination: The NIDA-SAMHSA blending initiative in the Clinical Trials Network. J Subst Abuse Treat 2010; 38(Suppl. 1):S31-S43.
44. Sindelar JL, Ebel B, Petry NM. What do we get for our money: Cost-effectiveness of adding contingency management. Addiction 2007; 102:309-316. (Pubitemid 46096293)
45. Hughes JR, Benowitz N, Hatsukami D, Mermelstein RJ, Shiffman S. Clarification of SRNT Workgroup guidelines for measures in clinical trials of smoking cessation therapies. Nicotine Tob Res 2004; 6(5):863-864. (Pubitemid 39504461)
46. Anton RE, Randall CL. Measurement and choice of drinking outcome variables in the COMBINE Study. J Stud Alcohol Suppl 2005; 15:104-109, discussion 92-93. (Pubitemid 41193184)
47. Kadden RM, Litt MD. Searching for treatment outcome measures for use across trials. J Stud Alcohol 2004; 65(1): 145-152. (Pubitemid 38200629)
48. Jacobson NS, Roberts LJ, Berns SB, McGlinchey JB. Methods for defining and determining the clinical significance of treatment effects: Description, application and alternatives. J Consult Clin Psychol 1999; 67:300-307. (Pubitemid 29266499)
49. Kendall PC,Marrs-Garcia A, Nath SR, Sheldrick RC. Normative comparisons for the evaluation of clinical significance. J Consult Clin Psychol 1999; 67:285-299. (Pubitemid 29266498)
50. Atkins DC, Bedics JD, McGlinchey JB, Beauchaine TP. Assessing clinical significance: Does it matter which method we use? J Consult Clin Psychol 2005; 73(5):982-989. (Pubitemid 41643248)
51. Cisler RA, Kowalchulk RK, Saunders SM, Zweben A, Trinh HQ. Applying clinical significance methodology to alcoholism treatment trials: Determining recovery outcome status with individual- and population-based measures. Alcohol Clin Exp Res 2005; 29:1991-2000. (Pubitemid 41790837)
52. Anton RF, OMalley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift RM, Weiss RD, Williams LD, Zweben A, for the COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE Study. J Am Med Assoc 2006; 2006:2003-2017. (Pubitemid 44794003)
53. Miller WR, Manuel JK. How large must a treatment effect be before it matters to practitioners? An estimation method and demonstration. Drug Alcohol Rev 2008; 27(5):524-528.
54. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, Schwartz JS. Rethinking randomized clinical trials for comparative effectiveness research: The need for transformational change. Ann Intern Med 2009; 151(3): 206-209.
55. Lauer MS, Collins FS. Using science to improve the nations health system: NIHs commitment to comparative effectiveness research. J Am Med Assoc 2010; 303(21):2182-2183.
56. Hien DA, Wells EA, Jiang H, Suarez-Morales L, Campbell AN, Cohen LR, Miele GM, Killeen T, Brigham GS, Zhang Y, Hansen C, Hodgkins C, Hatch-Maillette M, Brown C, Kulaga A, Kristman-Valente A, Chu M, Sage R, Robinson JA, Liu D, Nunes EV. Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders. J Consult Clin Psychol 2009; 77(4): 607-619.
57. Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS, Croghan IT, Adler LA, Weiss RD, Leimberger JD, Lewis DF, Dorer EM. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: A randomized, double-blind, placebocontrolled trial. J Clin Psychiatry 2010; 71:1680.
58. Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 2002; 59:877-883.
59. Nock MK. Conceptual and design essentials for evaluating mechanisms of change. Alcohol Clin Exp Res 2007; 31(S3):4S-12S. (Pubitemid 47437796)
60. McLellan AT, Kemp J, Brooks A, Carise D. Improving public addiction treatment through performance contracting: The Delaware experiment. Health Pol 2008; 87(3):296-308.
61. McHugh RK, Barlow DH. The dissemination and implementation of evidence-based psychological treatments. A review of current efforts. Am Psychol 2010; 65(2):73-84.
62. Proctor EK, Landsverk J, Aarons G, Chambers D, Glisson C, Mittman B. Implementation research in mental health services: An emerging science with conceptual, methodological, and training challenges. Adm Policy Ment Health 2009; 36(1):24-34.
63. Norquist G, Regier DA. The epidemiology of psychiatric disorders and the de facto mental health care system. Annu Rev Med 1996; 47:473-479. (Pubitemid 26138905)
64. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental health and addictive disorders service system: Epidemiological catchment area prospective one-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50:85-91.
65. McLellan AT, Carise D, Kleber HD. Can the national addiction treatment infrastructure support the publics demand for quality care? J Subst Abuse Treat 2003; 25:117-121. (Pubitemid 37415291)
66. McCarty D, McConnell KJ, Schmidt LA. Priorities for policy research on treatments for alcohol and drug use disorders. J Subst Abuse Treat 2010; 39(2):87-95.
67. Babor TF,McKee BG, Kassenbaum PA, Grimaldi PL, Ahmed K, Bray J. Screening, brief intervention, and referral to treatment (SBIRT): Toward a public health approach to the management of substance abuse. Subst Abus 2007; 28:7-30. (Pubitemid 350243063)
68. Carroll KM, Rounsaville BJ. Computer-assisted therapy in psychiatry: Be brave-its a new world. Curr Psychiatry Rep 2010; 12:426-432.
69. Bickel WK, Christensen DR, Marsch LA. A review of computer-based interventions used in the assessment, treatment, and research of drug addiction. Subst Use Misuse 2011; 46(1):4-9.
70. Bickel WK,Marsch LA, Buchhalter AR, Badger GJ. Computerized behavior therapy for opioid-dependent outpatients: A randomized controlled trial. Exp Clin Psychopharmacol 2008; 16(2):132-143. (Pubitemid 351680706)
71. Institute of Medicine. Improving the Quality of Health Care for Mental and Substance Use Conditions. Washington, DC: The National Academies Press, 2006
72. McLellan AT, Lewis DC, OBrien CP, Kleber HD. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. J Am Med Assoc 2000; 284:1689-1695.
73. McKay JR. Continuing care in the treatment of addictive disorders. Curr Psychiatry Rep 2006; 8(5):355-362. (Pubitemid 44515387)
74. McLellan AT. Congratulations on the 10-year anniversary of the National Drug Abuse Treatment Clinical Trial Network - now, whats new for the coming decade? J Subst Abuse Treat 2010; 38(Suppl. 1): S1-S3.
75. Carroll KM, Rounsaville BJ. A perfect platform: Combining contingency management with medications for drug abuse. Am J Drug Alcohol Abuse 2007; 33(3):343-365, PMCID: PMC2367002. (Pubitemid 47037172)